| Summary of TREC assay variation during the initial method verification |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | SAMPLES |  |  |  |
|  | n | $\mathbf{C a l ~ A}$ | $\mathbf{C 1}$ | $\mathbf{C 3}$ |
| SD (copies $/ \boldsymbol{\mu} \mathbf{L})$ | 28 | 0.74 | 0.38 | 0,44 |
| kit SD expected values |  | $<0.84$ | $<0.65$ | $<0.71$ |
| CV $(\%)$ | 28 | 85 | 39 | 46 |
| kit CV expected values |  | $<101$ | $<73$ | $<81$ |


|  | n | Value |
| :---: | :---: | :---: |
| LoD $(\operatorname{copies} / \boldsymbol{\mu L})$ | 20 | 3.4 |
| LoQ $(\operatorname{copies} / \boldsymbol{\mu})$ | 20 | 4.9 |
|  |  |  |
| External Quality assessment | 5 | $100 \%$ |
| Sensitivity | 3006 | $100 \%$ |
| Specificity | 3006 | $99.9 \%$ |
|  |  |  |
| Contamination risk | 111 | $0.9 \%$ |

Suppl. Mat. S1. Abbreviations: CV, coefficient of variation (\%); DBS, dry blood spot; LoD, limit of Detection (copies $/ \mu L$ ); LoQ, limit of Quantification (copies $\mu L$ ); SCID, severe combined immunodeficiency; SD, standard deviation (copies $/ \mu L$ ); TREC, T-cell receptor excision circle

- Calibrator A (Cal A), Control 1 and Control 2 were from lot 652072.
- Variation was expressed as standard deviations (SD) in the natural logarithmic (ln) scale and as CV\% in lognormal scale; both were compared with the kit supplier's SD and CV\% for the same range of values.
- LoD and LoQ calculated with a blank sample and very low TRECs sample analyzed during 10 days in duplicate and by calculating the critical value.
- External quality assessment was evaluated as a qualitative method (CDC Program, \% of successful results are indicated).
- Sensitivity was evaluated using 6 DBS samples from babies with confirmed SCID
- Contamination risk was evaluated with the C 2 control ( 0 copies $/ \mu \mathrm{L}$ ) and a blank paper (without sample). A result of $>10$ copies $/ \mu \mathrm{L}$ was considered as contamination.

Supplementary Material S2. SCID criteria defined by Kwan et al (2)
$\left.\begin{array}{|c|c|c|c|}\hline & \text { CD3 T Cells } / \mu \mathrm{L} & \text { PHA proliferation } & \text { Supporting features } \\ \hline \text { Typical SCID } & <300 & <10 \% \text { of normal } & \begin{array}{c}\text { Detectable maternal } \\ \text { T cells in peripheral } \\ \text { blood; proven } \\ \text { deleterious } \\ \text { defect(s) in a }\end{array} \\ \text { known SCID gene }\end{array}\right\}$

## Supplementary Material S3. List of $\mathbf{3 2 3}$ primary immunodeficiency disease genes included in our panel

| List of $\mathbf{3 2 3}$ primary immunodeficiency disease genes |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ACP5 | C4BPB | CD55 | CTSC | FERMT3 | ILIORB | LAT | MVK | PIK3R1 | RNF31 | TRAF3IP2 | TAP1 |
| ACTB | C5 | CD59 | CXCR4 | FOXN1 | IL12B | LCK | MYD88 | PLCG2 | RORC | TREXI | TAP2 |
| ADA | C6 | CD70 | СYВА | FOXP3 | ILI2RB1 | LIG1 | MYO5A | PMS2 | RPSA | TRNT1 | TAPBP |
| ADAM17 | C4A | CD79A | СуВВ | FPR1 | ILI7F | LIG4 | NBN | PNP | RTEL1 | TTC37 | TAZ |
| ADAMTS13 | C4B | CD79B | DCLREIB | G6PC | ILI7RA | LMNA | NBS1 | POLE1 | SAMHD 1 | TTC7A | TBK1 |
| ADAR | C4BPA | CD81 | DCLREIC | G6PC3 | ILI7RC | LPIN2 | NCF1 | PRF1 | SBDS | TYK2 | TBX1 |
| AICDA | C7 | CD8A | DEPTOR | G6PD | ILI8 | LRBA | NCF2 | PRKCD | SERPING1 | UNC119 | TCF3 |
| AIRE | C8A | CEBPE | DGKE | G6PT1 | ILIRN | LRRC8A | NCF4 | PRKDC | SH2D1A | UNC13D | TCIRG1 |
| AK2 | C8B | CECR1 | DKC1 | GATA2 | IL21 | LYST | NEIL3 | PSMB8 | SH3BP2 | UNC93B1 | TCN2 |
| AKT1 | C8G | CFB | DNMT3B | GFII | IL2IR | MAGT1 | NFAT5 | PSTPIPI | SKIV2L | TERC | TNFSF6 |
| AP3B1 | C9 | CFD | DOCK2 | GIMAP5 | IL2RA | MALT1 | NFKB1 | PTPRC | SLCl1A1 | TERT | TRAC |
| AP3D1 | CARD11 | CFH | DOCK8 | GP1BA | IL2RG | MAP3K14 | NFKB2 | RAB27A | SLC29A3 | TFRC | TRAF3 |
| AP4E1 | CARD14 | CFI | ELANE | HAXI | IL36RN | MASP1 | NFKBIA | RAC2 | SLC35C1 | THBD | UNG |
| APOL1 | CARD9 | CFP | ELF4 | ICOS | IL7R | MASP2 | NHEJI | RAG1 | SLC37A4 | TICAM1 | USB1 |
| ARPC1B | CARMIL2 | CHD7 | EPG5 | IFIH1 | INO80 | MBL2 | NHP2 | RAG2 | SLC46AI | TINF2 | VPREB1 |
| ATM | CASP10 | CIITA | F12 | IFNGR1 | IRAK4 | MCM10 | NLRC4 | RASGRP1 | SMARCALI | TLR3 | VPS13B |
| BLM | CASP8 | CLEC7A | $F A D D$ | IFNGR2 | IRF7 | MCM4 | NLRP12 | RASGRP2 | SP110 | TMC6 | VPS45 |
| BLNK | CD19 | CLPB | FAM105B | IGHAI | IRF8 | MEFV | NLRP3 | RBCK1 | SPINK5 | TMC8 | WAS |
| BLOCIS6 | CD247 | COH1 | FAS | IGHG2 | ISG15 | MKL1 | NOD2 | RECQL4 | Statl | TMEM173 | WASF2 |
| BTK | CD27 | COLEC11 | FASLG | IGHM | ITCH | MLPH | NOP10 | RFX5 | STAT2 | TNFAIP3 | WIPF1 |
| CIQA | CD3D | COPA | FCGR1A | IGLLI | ITGB2 | MMACHC | NRAS | RFXANK | STAT3 | TNFRSF11A | WRAP53 |
| ClQB | CD3E | CORO1A | FCGR2A | IKBA | ITK | MPO | ORAII | RFXAP | STAT5B | TNFRSF13B | XIAP |
| CIQC | CD3G | CR2 | FCGR2B | IKBKB | JAGN1 | MRE11A | PARN | RMRP | STIM1 | TNFRSF13C | XRCC4 |
| C1R | CD3Z | CSF2RA | FCGR3A | IKBKG | JAK2 | MS4A1 | PAX5 | RNASEH2A | STK4 | TNFRSF1A | ZAP70 |
| C1S | CD40 | CSF3R | FCGR3B | IKZF1 | JAK3 | MSH6 | PGM3 | RNASEH2B | STN1 | TNFRSF4 | ZBTB24 |
| C2 | CD40LG | CTLA4 | FCGRT | ILIO | KRAS | MSN | PIGA | RNASEH2C | STX11 | TNFRSF6 | ZNF345 |
| C3 | CD46 | CTPS 1 | FCN3 | IL10RA | LAMTOR2 | MTHFD1 | PIK3CD | RNF168 | STXBP2 | TNFSF12 |  |

## - frontiers

## Supplementary Material S4. Median TREC copy numbers at each gestational week



Suppl. Mat. S5. Error bars indicate $25^{\text {th }}$ and $75^{\text {th }}$ percentile TREC copy numbers at each gestational week. Median TREC levels in our cohort rose significantly between 28 and 32 weeks gestation, in accordance with T-cell maturation in this period, a wider period of time than those reported by other authors (4,18,26).

Abbreviations: TRECs: $T$-cell receptor excision circles

## SCID NBS in Catalonia

## Supplementary Material S5. Flow cytometry protocols

Peripheral whole blood ( $50 \mu \mathrm{~L}$ ) was incubated with a mix of specific conjugated monoclonal antibodies ( mAb ) from each panel and gently mixed for 20 min at room temperature (RT) in the dark. The composition of mAb , florochromes, and brands are specified in the following table:

| T B NK populations |  |  |
| :---: | :---: | :---: |
| Cluster of Differentiation | Fluorochrome | Brand |
| CD45 | FITC | Beckman Coulter |
| CD4 | RD1 | Beckman Coulter |
| CD8 | ECD | Beckman Coulter |
| CD3 | PC5 | Beckman Coulter |
| CD56 | RD1 | Beckman Coulter |
| CD19 | ECD | Beckman Coulter |
| Cluster of Differentiation | Fluorochrome | Brand |
| CD45RA | FITC | Becton Dickinson |
| CD45R0 | PE | Becton Dickinson |
| CD3 | ECD | Beckman Coulter |
| CD4 | PerCP | Becton Dickinson |
| CD8 | PE-Cy7 | Beckman Coulter |
|  | HLA-DR |  |
| Cluster of Differentiation | Fluorochrome | Brand |
| CD3 | ECD | Beckman Coulter |
| CD4 | APC | Cytognos |
| CD8 | PE-Cy7 | Beckman Coulter |
| HLA-DR | Pacific Blue | Beckman Coulter |

Samples were treated with 1 mL of VersaLyse lysing solution (Beckman Coulter), vortexed, and incubated for 15 min at RT in the dark. Samples were then washed with phosphate-buffered saline (PBS), stored at RT in the dark, and analyzed within 1 h . Samples were acquired with a Navios EX Flow Cytometer (Beckman Coulter), equipped with three lasers: a $405-\mathrm{nm}$ violet laser, a $488-\mathrm{nm}$ blue laser, and a $638-\mathrm{nm}$ red laser. At least 100,000 events were acquired from each sample. Flow cytometry data were analyzed with Kaluza software (Beckman Coulter).

